Innoviva Inc. (INVA)
INVA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1080014/000119312526071776/0001193125-26-071776-index.htm. Net income: SEC 10-K (us-gaap:ProfitLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | INVA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2004 |
| SEC CIK | 0001080014 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $411.3M |
| Net income | $271.2M |
| Operating income | $163.7M |
| Net margin | 65.9% |
| Operating margin | 39.8% |
| Revenue growth | +14.7% |
| Cash | $550.9M |
| Total assets | $1.6B |
| P/E (computed) | 4.8× |
| P/S (computed) | 3.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $581.4M cash; operating cash flow $45.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 71,081,477 (2026-10-31); 74,769,062 a year earlier; 64,086,675 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Jose, California, United States | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $106.1M | -$73.9M | $41.7M | $581.4M | $258.8M | $438.3M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $119.6M | -$83.4M | $52.0M | $570.4M | $258.5M | $440.0M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $98.0M | $186.6M | $35.3M | $603.1M | $258.1M | $420.7M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $114.6M | $164.2M | $54.5M | $550.9M | $257.7M | $411.3M | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | $107.8M | $89.9M | $49.7M | $476.5M | $257.4M | $388.5M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $100.3M | $63.7M | $44.1M | $397.5M | $448.9M | $370.2M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $88.6M | -$46.6M | $48.6M | $319.1M | $448.9M | $369.8M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $91.8M | $20.3M | $59.2M | $305.0M | $448.3M | $358.7M | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2013-01-18 |
| Latest annual report | 10-K/A | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEF 14A | 2026-03-24 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.4% |
| 1 month | -8.2% |
| 3 months | -8.3% |
| Year to date | -4.8% |
| 1 year | -14.3% |
| From 52-week high | -21.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OCUL | Ocular Therapeutix Inc. | $6.01 | -3.22% | $1.3B |
| AVLN | Avalyn Pharma Inc. | $29.76 | -1.72% | $1.3B |
| GPCR | Structure Therapeutics Inc. | $18.57 | -7.15% | $1.3B |
| MLYS | Mineralys Therapeutics Inc. | $14.53 | -5.22% | $1.3B |
| GHRS | GH Research PLC | $18.75 | -1.83% | $1.3B |
| GENB | Generate Biomedicines Inc. | $10.49 | -13.09% | $1.4B |
| NUVB | Nuvation Bio Inc. | $3.84 | -3.76% | $1.4B |
| MNKD | MannKind Corporation | $3.96 | -4.24% | $1.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier